CureVac GmbH is a biopharmaceutical company specializing in the prophylactic and therapeutic application of messenger RNA (mRNA). CureVac's lead programme is dedicated to the development of active immunotherapies (based on its RNActive® technology) for the treatment of prostate cancer and non-small cell lung cancer. Furthermore, in preclinical studies, CureVac is developing prophylactic vaccines and adjuvants to address infectious diseases.
Company Growth (employees)
Tübingen, DE
Size (employees)
151 (est)+2%
CureVac was founded in 2000 and is headquartered in Tübingen, DE

Key People/Management at CureVac

Ingmar Hoerr

Ingmar Hoerr

Chief Executive Officer
Mathias Hothum

Mathias Hothum

Baord of Directors
Franz-Werner Haas

Franz-Werner Haas

Chief Corporate Officer
Ulrike Gnad-Vogt

Ulrike Gnad-Vogt

Acting Chief Medical Officer
Mariola Fotin-Mleczek

Mariola Fotin-Mleczek

Acting Chief Scientific Officer

CureVac Office Locations

CureVac has offices in Tübingen, Frankfurt am Main and Boston
Tübingen, DE (HQ)
Paul-Ehrlich-Str. 15
Frankfurt am Main, DE
27 Schumannstraße
Tübingen, DE
15 Paul-Ehrlich-Straße
Boston, US
51 Melcher St

CureVac Financials and Metrics

Summary Metrics

CureVac's latest funding round in November 2016 was reported to be $29.5 m. In total, CureVac has raised $359 m. CureVac's latest valuation is reported to be $1.7 b.

CureVac Financials


Market valuation

1.7 b
Show all financial metrics

CureVac's Web-traffic and Trends

CureVac Online and Social Media Presence

CureVac News and Updates

Pharma’s Future: 100+ Startups Working Across Alzheimer’s, Diabetes, Cancer, And More

The pharmaceutical industry is changing at a rapid pace. The introduction of immunotherapy techniques such as CAR-T cell therapy and cancer vaccines are bringing oncology into the 21st century while CRISPR is poised to bring genetic editing into every clinic … Continued

CureVac Company Life and Culture

You may also be interested in